A Study of SNDX-5613 in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)

Syndax Pharmaceuticals logo

Syndax Pharmaceuticals

Status and phase

Enrolling
Phase 2
Phase 1

Conditions

Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Acute Lymphoblastic Leukemia
Mixed Lineage Acute Leukemia
Acute Myeloid Leukemia

Treatments

Drug: SNDX-5613
Drug: cobicistat

Study type

Interventional

Funder types

Industry

Identifiers

NCT04065399
2020-004104-34 (EudraCT Number)
SNDX-5613-0700

Details and patient eligibility

About

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of SNDX-5613 in participants with acute leukemia. In Phase 2, participants will be enrolled in 3 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of SNDX-5613.

Full description

Phase 1: Oral SNDX-5613; sequential cohorts of escalating dose levels of SNDX-5613 to identify the MTD and RP2D. Participants will be enrolled in one of six dose-escalation arms: Arm A: Participants not receiving any strong cytochrome P450 3A4 (CYP3A4) inhibitor/inducers or fluconazole. Arm B: Participants receiving itraconazole, ketoconazole, posaconazole, or voriconazole (strong CYP3A4 inhibitors) for antifungal prophylaxis. Arm C: Participants receiving SNDX-5613 and cobicistat. Arm D: Participants receiving fluconazole (moderate CYP3A4 inhibitor) for antifungal prophylaxis. Arm E: Participants not receiving any weak, moderate, or strong CYP3A4 inhibitors/inducers. Arm F: Participants receiving isavuconazole (moderate CYP3A4 inhibitor) for antifungal prophylaxis. In Phase 2, participants will be enrolled in 3 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of SNDX-5613: Cohort 2A: Participants with KMT2Ar acute lymphoblastic leukemia (ALL)/mixed phenotype acute leukemia (MPAL) Cohort 2B: Participants with KMT2A AML Cohort 2C: Participants with NPM1m AML

Enrollment

413 estimated patients

Sex

All

Ages

30+ days old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participants must have active acute leukemia (bone marrow blasts ≥5% or reappearance of blasts in peripheral blood) as defined by the National Comprehensive Cancer Network (NCCN) in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia (Version 1.2020) and Acute Myeloid Leukemia (Version 3.2020), or acute leukemia harboring KMT2A rearrangement, NUP98 rearrangement, or NPM1 mutation that have detectable disease in the bone marrow.

Phase 1:

  • Arm A: Participants not receiving any strong CYP3A4 inhibitor/inducers or fluconazole.
  • Arm B: Participants receiving itraconazole, ketoconazole, posaconazole, or voriconazole (strong CYP3A4 inhibitors) for antifungal prophylaxis.
  • Arm C: Participants receiving SNDX-5613 in combination with cobicistat.
  • Arm D: Participants receiving fluconazole (moderate CYP3A4 inhibitor).
  • Arm E: Participants not receiving any weak, moderate, or strong CYP3A4 inhibitors/inducers.
  • Arm F: Participants receiving isavuconazole (moderate CYP3A4 inhibitor) for antifungal prophylaxis.

Phase 2:

Documented R/R active acute leukemia (bone marrow blasts ≥5% or reappearance of blasts in peripheral blood) as defined by the NCCN Guidelines® for Acute Lymphoblastic Leukemia (Version 1.2020) and Acute Myeloid Leukemia (Version 3.2020).

  • Cohort 2A: Documented R/R ALL/MPAL with KMT2A rearrangement.
  • Cohort 2B: Documented R/R AML with KMT2A rearrangement.
  • Cohort 2C: Documented R/R AML with NPM1m.
  • White blood cell count below 25,000/ microliter at time of enrollment. Participants may receive cytoreduction prior to enrollment per protocol-specified criteria.
  • Male or female participants aged ≥30 days old.
  • Eastern Cooperative Oncology Group (ECOG) performance status score 0-2 or Karnofsky/Lansky score ≥50.
  • Any prior treatment-related toxicities resolved to ≤Grade 1 prior to enrollment, with the exception of ≤Grade 2 neuropathy or alopecia.
  • Radiation Therapy: At least 60 days from prior total body irradiation (TBI), craniospinal radiation and/or ≥50% radiation of the pelvis, or at least 14 days from local palliative radiation therapy (small port).
  • Stem Cell Infusion: At least 60 days must have elapsed from hematopoietic stem cell transplant and at least 4 weeks must have elapsed from donor lymphocyte infusion.
  • Immunotherapy: At least 42 days since prior immunotherapy, including tumor vaccines, and at least 21 days since receipt of chimeric antigen receptor therapy or other modified T or NK cell therapy.
  • Antileukemia Therapy: At least 14 days, or 5 half-lives, whichever is shorter, since the completion of antileukemic therapy.
  • Hematopoietic Growth Factors: At least 7 days since the completion of therapy with short-acting hematopoietic growth factors and 14 days with long-acting growth factors.
  • Biologics: At least 90 days, or 5 half-lives, whichever is shorter, since the completion of therapy with an antineoplastic biologic agent.
  • Steroids: At least 7 days since systemic glucocorticoid therapy, unless receiving physiologic dosing or cytoreductive therapy.
  • Adequate organ function.
  • If of childbearing potential, willing to use a highly effective method of contraception or double barrier method from the time of enrollment through 120 days following the last study drug dose.

Exclusion criteria

Participants meeting any of the following criteria are not eligible for study participation:

  • Diagnosis of active acute promyelocytic leukemia.
  • Isolated extramedullary relapse (Phase 2 only).
  • Active central nervous system disease (cytologic, such as any blasts on cytospin, or radiographic).
  • Detectable human immunodeficiency virus (HIV) viral load within the previous 6 months. Participants with a known history of HIV 1/2 antibodies must have viral load testing prior to study enrollment.
  • Hepatitis B or C.
  • Pregnant or nursing women.

Cardiac Disease:

  • Any of the following within the 6 months prior to study entry: myocardial infarction, uncontrolled/unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), life-threatening, uncontrolled arrhythmia, cerebrovascular accident, or transient ischemic attack.
  • Corrected QT interval (QTc) >450 milliseconds.

Gastrointestinal Disease:

  • any gastrointestinal issue of the upper GI tract that might affect oral drug absorption or ingestion (that is, gastric bypass, gastroparesis, etc).
  • Cirrhosis with a Child-Pugh score of B or C.
  • Graft-Versus-Host Disease (GVHD): Signs or symptoms of acute or chronic GVHD >Grade 0 within 4 weeks of enrollment. All transplant participants must have been off all systemic immunosuppressive therapy and calcineurin inhibitors for at least 4 weeks prior to enrollment. Participants may be on physiological doses of steroids.
  • Concurrent malignancy in the previous 2 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (for example, breast carcinoma, cervical cancer in situ, melanoma in situ) treated with potentially curative therapy, or concurrent low-grade lymphoma, that is asymptomatic and lacks bulky disease and shows no evidence of progression, and for which the participant is not receiving any systemic therapy or radiation.
  • In Phase 1 and Phase 2: Participants requiring the concurrent use of medications known or suspected to prolong the QT/QTc interval, with the exception of drugs with low risk of QT/QTc prolongation that are used as standard supportive therapies (for example, diphenhydramine, famotidine, ondansetron, Bactrim) and the azoles permitted in the relevant arms of Phase 1 and in Phase 2.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Sequential Assignment

Masking

None (Open label)

413 participants in 1 patient group

SNDX-5613
Experimental group
Description:
Phase 1: Oral SNDX-5613; sequential cohorts of escalating dose levels of SNDX-5613 to identify the MTD and RP2D. Participants will be enrolled in 1 of 6 dose-escalation arms: Arm A: Participants not receiving any strong CYP3A4 inhibitor/inducers or fluconazole Arm B: Participants receiving any strong CYP3A4 inhibitors for antifungal prophylaxis Arm C: Participants receiving SNDX-5613 and cobicistat Arm D: Participants receiving fluconazole for antifungal prophylaxis Arm E: Participants not receiving any weak, moderate, or strong CYP3A4 inhibitors/inducers Arm F: Participants receiving isavuconazole for antifungal prophylaxis Phase 2: Oral SNDX-5613; Following the determination of the RP2D in Phase 1, 3 indication-specific expansion cohorts will be enrolled as follows: Cohort 2A: Participants with KMT2Ar ALL/MPAL Cohort 2B: Participants with KMT2Ar AML Cohort 2C: Participants with NPM1m AML
Treatment:
Drug: cobicistat
Drug: SNDX-5613

Trial contacts and locations

48

Loading...

Central trial contact

Syndax Pharmaceuticals

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems